Overview

Insomnia Treatment Market is expected to grow at a CAGR of over 5.2% during the forecast period 2022 to 2028.

The growing cases of insomnia worldwide due to rising stress levels has led to the growth of this market. With rising geriatric population coupled with awareness about numerous therapies and treatments in the market, support and propel the market’s growth.

With advancements in technology and invention of better, efficient, new therapies providing quick, positive results, the public is more open to accepting such cures. Thus the increase in the launch of novel products such as Merck & Co.’s Belsomra is projected to fuel high demand. Moreover, the availability of multiple generics is expected to boost the insomnia therapeutics market over the forecast period. Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is expected to be launched in the near future, which may promote growth.
With new products and technology employed the market is estimated to soar unboundedly. Additionally, quite a few medical devices have been approved in the recent years such as EBB Insomnia Therapy, Fisher Wallace Stimulator, and Alpha-Stim AID, which are expected to have higher penetration due to favourable reimbursement policies and adoption of the device-drug combination therapies for treating insomnia.

North America was leading the insomnia therapeutics market and accounted for a major revenue share. Favourable reimbursement policies will further promote revenue growth.
North America is followed by the Asia Pacific, which is poised to grow at healthy CAGR. Emerging economies such as India, China, and Indonesia have been using generics and branded generics due to the economic pricing of generic alternatives. 
Asia Pacific is anticipated to witness lucrative growth over the forecast period with a high CAGR.

The global insomnia therapeutics market is highly fragmented with several manufacturers offering generics.

Major market players are Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals; Merck & Co., Inc.,Pfizer Inc.; Teva Pharmaceutical Industries Ltd.,Mylan N.V., Sumitomo Dainippon Pharma Co., Ltd, Sanofi, Paratek Pharmaceuticals Inc., Ebb Therapeutics.

Insomnia Treatment Market Segmentation:

By Drug Type
•  OTC Drugs
•  OTC Sleep Aids
•  OTC Sleep Supplements
•  Prescription Drugs

By Distribution Channel
•  Hospital Pharmacies
•  Retail Pharmacies
•  e-Commerce
•  Drug Stores
•  Others

By Region:
•  Europe 
•  North America 
•  APAC 
•  Latin America
•  Middle East and Africa

Competitive Landscape: 
•  Tier 1 players- established companies in the market with a major market share 
•  Tier 2 players
•  Emerging players which are growing rapidly
•  New Entrants    

FutureWise Takeaways: 
•  Growth prospects 
•  SWOT analysis
•  Key trends
•  Key data points affecting market growth 

Objectives of the Study:
•  To provide an exhaustive analysis on the global insomnia treatment market by drug type,  by distribution channel and by region
•  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•  To evaluate and forecast micro-markets and the overall market 
•  To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, Middle East and Africa
•  To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•  Profiling of companies to evaluate their market shares, strategies, financials and core competencies 

Flexible Delivery Model:
•  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•  The customization Mobility Care offered are free of charge with purchase of any license of the report
•  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
    2.1. Research Data 
         2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
                2.1.2.1. Key Data from Primary Sources
    2.2. Market Size Estimation 
    2.3. Market Breakdown and Data Triangulation 
    2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Insomnia Treatment Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Type Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Insomnia Treatment Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Insomnia Treatment Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Type Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Type Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Insomnia Treatment Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)
         7.1.  OTC Drugs
         7.2. OTC Sleep Aids
         7.3. OTC Sleep Supplements
         7.4. Prescription Drugs

8. Global Insomnia Treatment Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
         8.1. Hospital Pharmacies 
         8.2. Retail Pharmacies
         8.3. e-Commerce    
         8.4. Drug Stores
         8.5. Others

9. North America Insomnia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        9.2.1. U.S.A
        9.2.2. Canada
        9.2.3. Mexico
   9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Insomnia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. Brazil
          10.2.2. Venezuela
          10.2.3. Argentina
          10.2.4. Rest of Latin America
    10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Insomnia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Germany
          11.2.2. U.K         
          11.2.3. France
          11.2.4. Italy
          11.2.5. Spain
          11.2.6. Russia
          11.2.7. Poland
          11.2.8. Rest of Europe
    11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Insomnia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Japan
          12.2.2. China
          12.2.3. India
          12.2.4. Australia and New Zealand
          12.2.5. ASEAN
          12.2.6. Rest of Asia Pacific
    12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. GCC
          13.2.2. Israel
          13.2.3. South Africa
          13.2.4. Rest of MEA
    13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape   
    14.1. Global Landscape - Key Players, Revenue and Presence
    14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    14.3. Global Emerging Companies
    14.4. North America - Market Share Analysis and Key Regional Players
    14.5. Europe - Market Share Analysis and Key Regional Players
    14.6. Asia Pacific - Market Share Analysis and Key Regional Players
    14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
        15.1. Takeda Pharmaceutical Company Ltd.
                   15.1.1. Company Overview
                   15.1.2. Product Portfolio
                   15.1.3. SWOT Analysis
                   15.1.4. Financial Overview
                   15.1.5. Strategic Overview
         15.2. Vanda Pharmaceuticals
                   15.2.1. Company Overview
                   15.2.2. Product Portfolio
                   15.2.3. SWOT Analysis
                   15.2.4. Financial Overview
                   15.2.5. Strategic Overview
         15.3.  Merck & Co.Inc.
                   15.3.1. Company Overview
                   15.3.2. Product Portfolio
                   15.3.3. SWOT Analysis
                   15.3.4. Financial Overview
                   15.3.5. Strategic Overview
         15.4. Pfizer Inc.
                   15.4.1. Company Overview
                   15.4.2. Product Portfolio
                   15.4.3. SWOT Analysis
                   15.4.4. Financial Overview
                   15.4.5. Strategic Overview
         15.5 Teva Pharmaceutical Industries Ltd.
                  15.5.1. Company Overview
                  15.5.2. Product Portfolio
                  15.5.3. SWOT Analysis
                  15.5.4. Financial Overview
                  15.5.5. Strategic Overview
         15.6 Mylan N.V.
                  15.6.1. Company Overview
                  15.6.2. Product Portfolio
                  15.6.3. SWOT Analysis
                  15.6.4. Financial Overview
                  15.6.5. Strategic Overview
         15.7. Sumitomo Dainippon Pharma Co. Ltd.
                  15.7.1. Company Overview
                  15.7.2. Product Portfolio
                  15.7.3. SWOT Analysis
                  15.7.4. Financial Overview
                  15.7.5. Strategic Overview
         15.8. Sanofi
                  15.8.1. Company Overview
                  15.8.2. Product Portfolio
                  15.8.3. SWOT Analysis
                  15.8.4. Financial Overview
                  15.8.5. Strategic Overview
         15.9. Paratek Pharmaceuticals Inc.
                  15.9.1. Company Overview
                  15.9.2. Product Portfolio
                  15.9.3. SWOT Analysis
                  15.9.4. Financial Overview
                  15.9.5. Strategic Overview
          15.10.Ebb Therapeutics
                  15.10.1. Company Overview
                  15.10.2. Product Portfolio
                  15.10.3. SWOT Analysis
                  15.10.4. Financial Overview
                  15.10.5. Strategic Overview
          15.11. Sonafi
                  15.11.1. Company Overview
                  15.11.2. Product Portfolio
                  15.11.3. SWOT Analysis
                  15.11.4. Financial Overview
                  15.11.5. Strategic Overview

16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures